Clinical trials: Epirubicin
Breast Cancer
Combination Chemotherapy in Treating Women With Resected Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any tumor cells remaining after surgery.
- Trial name
- NCT00033683
- Testing
- CMF regimen, cyclophosphamide, docetaxel
- Where
- 69 sites in Belgium, United Kingdom
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
This 3 arm study will assess the tolerability, safety and efficacy of 3 neoadjuvant treatment regimens in participants with locally advanced, inflammatory or early stage human epidermal growth factor receptor 2 (HER2)-positive…
- Trial name
- NCT00976989
- Testing
- Pertuzumab, Trastuzumab, FEC
- Where
- 55 sites in Bosnia and Herzegovina, Brazil and 18 more
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection
The aim of this study is to analyze the therapeutic effect of adjuvant TACE after resection.Patients receiving curative resection (R0) were randomized to postoperative TACE group and no TACE group.
- Trial name
- NCT00820053
- Testing
- epirubicin and lipiodol
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Breast Cancer
Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
RATIONALE: Drugs used in chemotherapy such as epirubicin and docetaxel use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00066443
- Testing
- pegfilgrastim, docetaxel, epirubicin hydrochloride
- Where
- 5 sites in Canada
- Volunteers
- 93 people
- Sponsor
- NCIC Clinical Trials Group
Gastric Cancer
A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.
This study will assess the safety and efficacy of Xeloda, given in combination with standard chemotherapy regimens, for the first-line treatment of advanced and/or metastatic gastric cancer.
- Trial name
- NCT00454636
- Testing
- Cisplatin, Capecitabine, Epirubicin
- Where
- 51 sites in Spain
- Volunteers
- 158 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Open label multicentric phase II randomized trial, using high throughput genome analysis as a therapeutic decision tool, which aims at comparing a targeted treatment administered according to the identified molecular anomalies of…
- Trial name
- SAFIR02_Breast (NCT02299999)
- Testing
- AZD2014, AZD4547, AZD5363
- Where
- 25 sites in France
- Volunteers
- 1,460 people
- Sponsor
- UNICANCER
Breast Cancer
Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer
The rationale of this randomized phase II study is to investigate the feasibility of sequenced densified FEC and docetaxel based regimens in patients with primary operable high-risk breast cancer.
- Trial name
- NCT00256360
- Testing
- dose dense with neulasta
- Where
- Belgium
- Volunteers
- 117 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Advanced Gastric Cancer
Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)
Recently, 3-drug (ECX) and 2-drug (CX) combination chemotherapy involving capecitabine showed promising results in randomized clinical trials for advanced gastric cancer (AGC).
- Trial name
- NCT00743964
- Testing
- Epirubicin, Cisplatin, capecitabine
- Where
- South Korea
- Volunteers
- 91 people
- Sponsor
- Samsung Medical Center
Breast Neoplasms
A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old
Manifold data revealed that young breast cancer patients are characterized by aggressive clinical history. The purpose of this study is to evaluate the efficacy and safety of different strategies incorporating paclitaxel to…
- Trial name
- NCT01026116
- Testing
- Epirubicin, Cyclophosphamide, Paclitaxel
- Where
- China
- Volunteers
- 521 people
- Sponsor
- Fudan University
Triple Negative Breast Cancer
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and…
- Trial name
- IMpassion030 (NCT03498716)
- Testing
- Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin
- Where
- 364 sites in United States, Argentina and 29 more
- Volunteers
- 2,199 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer
Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer
Anthracycline-taxane regimens are effective means of postponing progression in metastatic breast cancer. It is yet unclear whether addition of capecitabine to this combination improves the treatment outcome.
- Trial name
- TEX (NCT01433614)
- Testing
- Epirubicin, Paclitaxel, Capecitabine
- Where
- 9 sites in Sweden
- Volunteers
- 304 people
- Sponsor
- Thomas Hatschek
HR+/HER2- Breast Cancer
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
The neoadjuvant treatment options commonly used for HR+/HER2- breast cancer are mainly anthracycline sequential or combined with paclitaxel chemotherapy regimens.
- Trial name
- NCT06860529
- Testing
- Serplulimab, Epirubicin, Albumin Paclitaxel
- Where
- China
- Volunteers
- 357 people
- Sponsor
- Henan Cancer Hospital
Diffuse Large B Cell Lymphoma
The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.
This is a prospective, single-center, open-label clinical study designed to evaluate the efficacy and safety of the Zanubrutinib, Lenalidomide and Rituximab (ZR2) versus rituximab combined with CHOP or CDOP (R-CHOP or R-CDOP) in…
- Trial name
- NCT05428670
- Testing
- Zanubrutinib+Rituximab+Lenalidomide, RCHOP/RCDOP
- Where
- China
- Volunteers
- 150 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
TNBC, Triple Negative Breast Cancer
Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer
This study is a multicenter, single-arm, investigator-initiated Phase II clinical trial. Eligible patients with treatment-naive early or locally advanced triple-negative breast cancer (TNBC), clinically staged as Stage II-III…
- Trial name
- NCT06977542
- Testing
- Ivonescimab
- Volunteers
- 53 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma
In this study, patients with hepatocellular carcinoma were used as the research object to explore the effectiveness and safety of idarubicin hepatic artery perfusion combined with lipiodol embolization, and to preliminarily…
- Trial name
- NCT05053386
- Testing
- Idarubicin Hydrochloride for Injection, Epirubicin
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Neoplasm, Gastric Neoplasm
Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer
The prognosis for patients with advanced oesophago-gastric cancer is poor. Approximately 16,000 patients in the United Kingdom die from the disease.
- Trial name
- NCT01870791
- Testing
- Omegaven
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- University Hospitals, Leicester
Testicular Neoplasms
High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II
High-dose chemotherapy (HD-CT) is able to circumvent platinum-resistance of resistant/refractory germ-cell tumors (GCTs), but expectancy of cure remains low. New strategies are needed with new drugs and a sequential approach.
- Trial name
- NCT00231582
- Testing
- epirubicin, high-dose and autologous stem cell transplantation, paclitaxel
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Metastatic Advanced Gastric Cancer
A Comparative Study of Salvage Treatment With Combination of Docetaxel and Epirubicin
A salvage treatment with combination of docetaxel and epirubicin in patients with unresectable, metastatic gastric cancer after fluoropyrimidine failure : A HER2 status-based study
- Trial name
- NCT01624025
- Testing
- Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks
- Where
- South Korea
- Volunteers
- 22 people
- Sponsor
- Yonsei University
Gastric Cancer
Peri-operative Chemotherapy With ECX or XP in the Treatment of Advanced Gastric Cancer
The purpose of this study is to evaluate the safety and the effect of perioperative chemotherapy in the treatment of advanced gastric cancer.
- Trial name
- NCT01558947
- Testing
- Peri-operative chemotherapy of ECX, Peri-operative chemotherapy of XP
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00379015
- Testing
- trastuzumab, cyclophosphamide, docetaxel
- Where
- 5 sites in Japan
- Volunteers
- 38 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan